Trivedi and Lawitz discuss seladelpar’s mechanism of action and its use as a second-line therapy in PBC.
Emerging Role of Seladelpar in PBC Care
Trivedi and Lawitz discuss the clinical impact of having seladelpar as a second-line treatment option for patients with PBC.
Trivedi and Lawitz discuss what sets seladelpar apart from other PBC therapies in the rapidly evolving treatment landscape.
Trivedi and Lawitz review long-term data from the phase 3 open-label ASSURE study and explain what they add to our understanding of seladelpar for PBC.
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
5